CapsoVision, Inc. (CV) Stock

CapsoVision, Inc. (CV) is a Healthcare stock trading at $5.91 (as of 2026-08-20), with a market capitalization of $306.29M and a trailing P/E of 1.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Medical‑technology company developing advanced capsule endoscopy systems (CapsoCam Plus, CapsoCam Colon) and AI-enabled imaging platforms for gastrointestinal diagnostics

Understand CapsoVision, Inc.: how it makes money

CapsoVision develops capsule endoscopy systems and AI-enabled imaging platforms for gastrointestinal diagnostics, and it generates company revenue from these medical-technology offerings.

Its profit model is structurally tied to commercialization and adoption of its capsule endoscopy systems (CapsoCam Plus, CapsoCam Colon) and its AI-enabled imaging platforms for gastrointestinal diagnostics.

Business quality (Weak): The provided dataset includes product descriptions and high-level margins, but no reportable segment breakdown and no operational KPI candidates, which limits how precisely we can analyze drivers of results.

Valuation: At 5× earnings, CV trades 83% below the Medical Equipment average (32×). Note: one-time items can distort reported P/E.

Bull case

  • Product and platform focus in GI diagnostics: The company develops capsule endoscopy systems (CapsoCam Plus, CapsoCam Colon) and AI-enabled imaging platforms for gastrointestinal diagnostics.
  • Positive gross profitability in the latest period: Gross margin is reported at 47.6% for the period ended 2026-03-31.

Bear case

  • Deep operating losses: Operating margin is reported at -254.0% for the period ended 2026-03-31.
  • Reported revenue is 0.0B in the latest period: Revenue_b is reported as 0.0B for the period ended 2026-03-31, which raises questions about scale or disclosure for the period shown.
Valuation — source: SEC EDGAR (first-party)
Price$5.91
Market Cap$306.29M
P/E Ratio1.9
EV / EBITDA-10.2
Price / Book23.26
Price / Sales22.05
FCF Yield-9.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$13.55M
Net Margin-186.8%
Return on Equity-226.6%
Current Ratio3.35
Revenue Growth (YoY)15.3%
EPS Growth (YoY)-89.5%
FCF Growth (YoY)13.4%
Financial Health — source: SEC EDGAR
Altman Z-Score20.96 (safe)
Valuation vs Sector & Industry
Stock P/E1.9
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
vs Sector-91.0%
vs Industry-94.1%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($9.51M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOKang Huai Wang
Employees90
CountryUS
IPO Date2001-09-03

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • CeriBell, Inc. (CBLL)
  • Electromed, Inc. (ELMD)
  • Stereotaxis, Inc. (STXS)
  • FONAR Corporation (FONR)
  • Vivani Medical, Inc. (VANI)
  • electroCore, Inc. (ECOR)
  • Hyperfine, Inc. (HYPR)
  • Streamex Corp. (STEX)
CV earnings history · CV institutional & insider holders · CV KPIs & operating metrics · CV financials · CV investor presentations & press releases · CV SEC filings · CV peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.